Therapeutic Trials and Prognostic Markers for Adrenal Diseases - Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients
Massimo Terzolo, MD
University of Turin San Luigi Hospital, Italy
Presentations in This Video
Therapeutic Trials and Prognostic Markers for Adrenal Diseases - Biochemical Tumor Marker Status and Its Role in Treatment Response in Patients Who Received High-Specific-Activity I-131 MIBG in Advanced Pheochromocytoma and Paraganglioma (PPGL): Results From a Pivotal Phase 2 Clinical Trial
Camilo Jimenez, MD
UT MD Anderson Cancer Center, TX, United States
Therapeutic Trials and Prognostic Markers for Adrenal Diseases - Chair
Katja Kiseljak-Vassiliades, DO
University of Colorado Denver, CO, United States
Therapeutic Trials and Prognostic Markers for Adrenal Diseases - Mortality and Specific Causes of Death in Endogenous Cushing’s Syndrome: A Systematic Review, Meta-Analysis and Meta-Regression
Padiporn Limumpornpetch, Endocrinologist
University of Leeds, United Kingdom
Therapeutic Trials and Prognostic Markers for Adrenal Diseases - Modified GRAS Score for Prognostic Classification of Adrenocortical Carcinoma: An ENSAT Multicentre Study
Yasir Elhassan, MD
University of Birmingham, United Kingdom